Global

Sep 25, 2018
In the face of the booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports.
Sep 06, 2018
Tyrosine-kinase inhibitors (TKIs) are gradually becoming the most popular option for lung cancer treatment in China. Jin Zhang reports.
Aug 24, 2018
A recently announced collaboration between EUnetHTA, WHO, and ISPOR brings home the fact that there is still no real agreement on a definition of HTA, writes Reflector.
Aug 22, 2018
Using the joint price negotiations developed across Europe as the Beneluxa Initiative on Pharmaceutical Policy as a case study, Maude Schmidt and Giovanni Saldutti explore the implications of such intergovernmental initiatives.
Aug 21, 2018
Pharmaceutical Executive
Record capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.
Aug 20, 2018
In an attempt to reduce high drug prices and improve its medical insurance coverage, China has initiated a series of new moves, including the recent zero import tax on a range of anticancer drugs. Jin Zhang reports.
Aug 10, 2018
Pharmaceutical Executive
Most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth.
Aug 06, 2018
Pharmaceutical Executive
Over the last decade, Spain has seen a significant growth in venture-capital investment in the life sciences. We explore the driving forces.
Aug 01, 2018
Research-based companies in Europe look as though they have lost one battle on preserving incentives for innovation – but the bigger war is only now getting underway, writes Reflector.
Jul 31, 2018
By Pharmaceutical Executive Editors
native1_300x100
lorem ipsum